Becker Frank, Siemer Stefan, Hack Markus, Humke Ulrich, Ziegler Manfred, Stöckle Michael
Department of Urology and Paediatric Urology, Homburg, University of the Saarland, Germany.
Eur Urol. 2006 Jun;49(6):1058-63; discussion 1063-4. doi: 10.1016/j.eururo.2006.03.003. Epub 2006 Mar 23.
Elective nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) < 4 cm has been accepted as alternative to radical nephrectomy (RN). However, NSS for tumours > 4 cm is controversial. We present our experiences and long-term oncologic outcome of RCC > 4 cm treated with NSS in a retrospective single-institutional analysis of 69 patients.
Between 1975 and 2004, elective NSS was performed in 368 patients at our institution, including 69 patients with sporadic, nonmetastatic RCC > 4 cm. Overall and cancer-specific survivals were estimated using the Kaplan-Meier method.
Complications were seen in nine patients (13.0%). After a mean follow-up of 6.2 yr (median, 5.8 yr) seven patients (10.1%) had died, none of them of tumour-related causes. Tumour recurrence was detected in four patients (5.8%). The 5-yr overall survival probability was 94.9%. The 10-yr and 15-yr overall survival rates were both 86.7%. Cancer-specific survival was 100% after 5, 10, and 15 yr.
Selected patients with localized RCC even > 4 cm can be treated with elective NSS providing optimal long-term outcome. The surgeon's decision for organ-preserving surgery should depend on tumour localisation and technical feasibility rather than on tumour size.
对于直径小于4cm的肾细胞癌(RCC),选择性保留肾单位手术(NSS)已被视为根治性肾切除术(RN)的替代方案。然而,对于直径大于4cm的肿瘤行NSS仍存在争议。我们通过对69例患者进行回顾性单中心分析,介绍了直径大于4cm的RCC行NSS的经验及长期肿瘤学结局。
1975年至2004年间,我们机构对368例患者进行了选择性NSS,其中包括69例散发性、非转移性且直径大于4cm的RCC患者。采用Kaplan-Meier法估计总生存率和癌症特异性生存率。
9例患者(13.0%)出现并发症。平均随访6.2年(中位数为5.8年)后,7例患者(10.1%)死亡,均非肿瘤相关原因。4例患者(5.8%)检测到肿瘤复发。5年总生存概率为94.9%。10年和15年总生存率均为86.7%。5年、10年和15年后癌症特异性生存率均为100%。
即使是直径大于4cm的局限性RCC患者,经选择后行选择性NSS可获得最佳长期结局。外科医生决定行保肾手术应取决于肿瘤定位和技术可行性,而非肿瘤大小。